20 May 2020News UpdateNovalis Biotech Incubation to invest in CergentisNovalis Biotech Incubation, a Belgian venture capital investment fund, is investing seed capital in Cergentis for an undisclosed amount....Read more 16 March 2020News UpdateCOVID-19In light of the ongoing COVID-19 outbreak, we wish to briefly update you......Read more 6 January 2020News UpdateLaunch new websiteNew year, new website...Read more 12 December 2019Press ReleaseCergentis launches TLA technology for complete cancer gene mutation sequencingUTRECHT, THE NETHERLANDS - 07:00 CET, December 12, 2019 - Cergentis, a genomics company that develops and commercialises kits and services based on its propriet...Read more 1 November 2019News UpdateCergentis appoints new CFOIt is a true pleasure to announce that Jean-Marc Roelandt has joined Cergentis as Chief Financial Officer. Jean-Marc is a senior level executive with more than ...Read more 16 September 2019Press ReleaseCergentis appoints new boardUtrecht, The Netherlands - September 16, 2019. Cergentis, a genomics company that develops and commercializes kits and services based on its proprietary Targete...Read more 11 September 2019News UpdateCergentis on track with product development of TLA-based targeted complete next generation sequencing on FFPE samples for cancer diagnosticsBy combining proximity ligation with improved targeting strategies, we are able to sequence genes of interest completely, over a large width of 100’s of kilobas...Read more 8 September 2019PublicationsPacBio & Cergentis: TLA and Long-Read SequencingPacific Biosciences and Cergentis have presented the combination of TLA and the Pacific Biosciences SMRT sequencing technology...Read more
© 2012-2020 Cergentis B.V. All rights reserved.
For Research Use Only.Not for use in diagnostic procedures.